Browsing by Author "Pira, D."

Now showing 1 - 3 of 3

Citation - Scopus: 1
Immunity Unveiled: a Translational Network for Tackling Parkinson's Disease – Immuparknet
(F1000 Research Ltd, 2025) Gugu, M.; Acharya, S.; Pira, D.; Poletti, S.; di Flora, A.; Saksida, T.; Figueira, I.
Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD. Copyright: © 2025 Gugu M et al.
Citation - Scopus: 1
Immunity Unveiled: a Translational Network for Tackling Parkinson's Disease – Immuparknet
(F1000 Research Ltd, 2025) Gugu, M.; Acharya, S.; Pira, D.; Poletti, S.; di Flora, A.; Saksida, T.; Figueira, I.
Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD. Copyright: © 2025 Gugu M et al.
Citation - WoS: 1
Citation - Scopus: 1
Prevalence and Distribution of High-Risk Human Papillomavirus in Western Türkiye Between 2019 and 2022
(Akademiai Kiado ZRt., 2023) Ece, G.T.; Pira, D.; Bodur, G.L.
Human Papillomavirus (HPV) is a primarily sexually transmitted human pathogen linked with the formation of anogenital warts and several types of cancer including cervical cancer, oropharyngeal cancer, penile cancer, and anal cancer. HPV genotypes are divided into high-risk and low-risk in accordance with their potential for carcinogenesis. The most notable high-risk genotypes are HPV-16 and HPV-18. In this study we report on the PCR analysis results of the cervical smear results of 328 females, and 50 males who have presented to a tertiary care university hospital in the port city of İzmir, Türkiye between August 2019 and August 2022. HPV-DNA positivity percentage was determined as 25.3% (96/378). 5 of 378 patients were HPV-18 positive (age range 31-80) whereas 27 patients were HPV-16 positive (age range 29-66). 64 patients were positive for other high-risk HPV types (age range 27-56). The positivity for HPV-16, HPV-18 and other high-risk HPV types were determined as 7.14%, 1.3% and 16.9% respectively. Our results demonstrate a 25.3% (96/378) positivity among tested patients moreover, out of 96 positive cases at least 32 are vaccine preventable. This study indicates the need for higher coverage of HPV vaccination in Western Türkiye. © 2023 Akadémiai Kiadó, Budapest.